Emiliem, Inc., a privately-held biopharmaceutical company, has a significant intellectual property portfolio and has established collaboration and services agreements covering all aspects of early oncology R&D.  The Company is developing Molecular Targeted Therapeutics (MTTs) for oncology and other indications.  MTTs are novel therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases.

Our clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays. This approach allows us to determine if a drug candidate works as designed and creates significant value for each drug candidate after the initial clinical trials in cancer patients. Since relevant clinical data derived from these trials can establish proof of mechanism, this strategy substantially increases the probability of success in future development and commercialization.